Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study on Tocolysis in Prevention of Preterm Labour
Brief Summary: Preterm birth is defined as birth before 37 completed weeks of gestation .it occurs in 11.1%of birth globally affecting an estimated 14.9 million babies every year . It is generally accepted that approximately 65%-70%of preterm births are spontaneous,40%-45% of them due to spontaneous preterm labor and 25%-30%following preterm rupture of membranes.preterm birth represents the single largest cause of morbidity and mortality for newborn and is estimated for 29%of deaths in the first four weeks of life and also is estimated for of major cause of morbidity for pregnant women .

Tocolytic agents include a wide range of drugs that can slow or suppress uterine contractions . Tocolytic are considered advantages in spontaneous preterm labor to : (a) allow time for the fetus to mature ,potentially avoiding deleterious effects of pre-maturity . (b)allow time for antenatal corticosteroids to be administered and have clinical effect. (c) allow time for intrauterine transfer to higher-care center where neonatal intensive care facilities are available . the ideal Tocolytic agent should be effective , easy to administer , without significant material ,fetal or neonatal side effects and permit time for antenatal corticosteroids to be administered and take effect . a variety of Tocolytic treatments have been used to inhibit uterine activity in women in spontaneous preterm labor , including betamimetics , calcium channel blockers , magnesium sulfate , prostaglandin inhibitors and oxytocin receptor antagonists however there is considerable global variation in types , doses and regimens of tocolytic agents uses to manage preterm labor .

A comparison study between Ritodrine, magnesium sulfate and Nifedipine in terms of effect and morbidity will be conducted.


Options:
A: Arm Label: Nifedipine (60 mg / day orally); Type: ACTIVE_COMPARATOR; Interventions: Drug: nifedipine (60 mg / day orally) | Arm Label: Progesterone 200 mg / day vaginally; Type: ACTIVE_COMPARATOR; Interventions: Drug: progesterone 200 mg / day vaginally | Intervention Type: DRUG; Name: progesterone 200 mg / day vaginally; Assigned to Arm(s): Progesterone 200 mg / day vaginally | Intervention Type: DRUG; Name: nifedipine (60 mg / day orally); Assigned to Arm(s): Nifedipine (60 mg / day orally)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nifedlipine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium | Intervention Type: DRUG; Name: Magnesium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Nifedlipine; Assigned to Arm(s): 1
C: Arm Label: Magnesium sulphate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: Ritodrine; Type: EXPERIMENTAL; Interventions: Drug: Ritodrine | Arm Label: Calcium channel blocker; Type: EXPERIMENTAL; Interventions: Drug: Calcium Channel Blockers | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Magnesium sulphate | Intervention Type: DRUG; Name: Ritodrine; Assigned to Arm(s): Ritodrine | Intervention Type: DRUG; Name: Calcium Channel Blockers; Assigned to Arm(s): Calcium channel blocker
D: Arm Label: Utrogestan; Type: ACTIVE_COMPARATOR; Interventions: Drug: utrogestan | Arm Label: Nifedipine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: utrogestan; Assigned to Arm(s): Utrogestan | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine

Answer: C